+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2020

  • ID: 5017429
  • Drug Pipelines
  • March 2020
  • Region: Global
  • 151 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Achelios Therapeutics Inc
  • Bristol-Myers Squibb Co
  • KannaLife Sciences Inc
  • NeurExo Sciences LLC
  • Regulonix LLC
  • Trevena Inc
  • MORE
Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2020, provides an overview of the Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline landscape.

Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes and balance problems. Risk factors include longer duration of therapy, pre-existing neuropathy and type of chemotherapeutic agent.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 6, 20 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Peripheral Neuropathy (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Achelios Therapeutics Inc
  • Bristol-Myers Squibb Co
  • KannaLife Sciences Inc
  • NeurExo Sciences LLC
  • Regulonix LLC
  • Trevena Inc
  • MORE
  • Introduction
  • Chemotherapy Induced Peripheral Neuropathy - Overview
  • Chemotherapy Induced Peripheral Neuropathy - Therapeutics Development
  • Chemotherapy Induced Peripheral Neuropathy - Therapeutics Assessment
  • Chemotherapy Induced Peripheral Neuropathy - Companies Involved in Therapeutics Development
  • Chemotherapy Induced Peripheral Neuropathy - Drug Profiles
  • Chemotherapy Induced Peripheral Neuropathy - Dormant Projects
  • Chemotherapy Induced Peripheral Neuropathy - Discontinued Products
  • Chemotherapy Induced Peripheral Neuropathy - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Achelios Therapeutics Inc, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Apexian Pharmaceuticals Inc, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Aphios Corp, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Aptinyx Inc, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Asahi Kasei Pharma Corp, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Bristol-Myers Squibb Co, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Candel Therapeutics, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Disarm Therapeutics Inc, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Emerald Bioscience Inc, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Exodos Life Sciences Limited Partnership, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Immune Pharmaceuticals Inc, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by KannaLife Sciences Inc, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Kineta Inc, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by MAKScientific LLC, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Metys Pharmaceuticals AG, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Mundipharma International Ltd, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by NeurExo Sciences LLC, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Osmol Therapeutucs Inc, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by PharmatrophiX Inc, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by PledPharma AB, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Regulonix LLC, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Sensei Biotherapeutics Inc, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by SiteOne Therapeutics Inc, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Sonnet BioTherapeutics Inc, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Sova Pharmaceuticals Inc, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Stealth BioTherapeutics Corp, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Toray Industries Inc, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Trevena Inc, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by WEX Pharmaceuticals Inc, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Winsantor Inc, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by YD Life Science Co, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Chemotherapy Induced Peripheral Neuropathy - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Achelios Therapeutics Inc
  • Apexian Pharmaceuticals Inc
  • Aphios Corp
  • Aptinyx Inc
  • Asahi Kasei Pharma Corp
  • Bristol-Myers Squibb Co
  • Candel Therapeutics
  • Disarm Therapeutics Inc
  • Emerald Bioscience Inc
  • Exodos Life Sciences Limited Partnership
  • Immune Pharmaceuticals Inc
  • KannaLife Sciences Inc
  • Kineta Inc
  • Kyorin Pharmaceutical Co Ltd
  • MAKScientific LLC
  • Metys Pharmaceuticals AG
  • Mundipharma International Ltd
  • NeurExo Sciences LLC
  • Osmol Therapeutucs Inc
  • PharmatrophiX Inc
  • PledPharma AB
  • Regulonix LLC
  • Sensei Biotherapeutics Inc
  • SiteOne Therapeutics Inc
  • Sonnet BioTherapeutics Inc
  • Sova Pharmaceuticals Inc
  • Stealth BioTherapeutics Corp
  • Toray Industries Inc
  • Trevena Inc
  • WEX Pharmaceuticals Inc
  • Winsantor Inc
  • YD Life Science Co
Note: Product cover images may vary from those shown
Adroll
adroll